HDAC9 and neoplasm: In 2022, researchers demonstrated that inhibition of EZH2 and HDAC could reactivate IFI16-directed immune response of HER2-positive BC patients, changing “cold tumor” into “hot tumor”, and sensitizing anti-HER2 treatment responses [38].